

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

POSITIVE PROFIT ALERT

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (“**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the Group’s unaudited consolidated management accounts for the year ended December 31, 2021, it is expected that the Group will record a profit attributable to equity shareholders of the Company of approximately RMB1,480 million to RMB1,540 million for the year ended December 31, 2021, representing an increase of approximately RMB810 million to RMB870 million, or approximately 121% to 130%, as compared to the profit attributable to equity shareholders of the Company for the year ended December 31, 2020. Such increase was mainly attributable to: (i) the rapid increase in revenue from Sanbexin (edaravone and dexborneol concentrated solution for injection), a Class I innovative drug developed originally which was launched in July 2020; (ii) the gain recorded by the Group from the disposal of its entire equity interest in Simgene Group Limited, and (iii) increased investment gains due to the fair value changes of portfolios held by the Group. Simultaneously, the impact of the profit above is partially counteracted by the following factors: (i) the continuous increase in the research and development costs for rapid advancement of the clinical pipeline in 2021; and (ii) the increase in the marketing expenses for accelerating the promotion of the newly launched products more efficiently, such as the innovative drug Sanbexin.

The Company is still in the process of finalising the annual results of the Group for the year ended December 31, 2021. The information contained in this announcement is based solely on the preliminary assessment of the Group’s unaudited consolidated management accounts for the year ended December 31, 2021 and is subject to finalisation and other potential adjustments, if any, and has not been reviewed or confirmed by the Group’s auditors or the audit committee of the Board. Shareholders and potential investors of the Company should refer to the Group’s annual results announcement for the year ended December 31, 2021, which is expected to be published by the end of March 2022.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sincere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, February 21, 2022

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. WAN Yushan and Mr. TANG Renhong as the executive Directors; Mr. ZHAO John Huan as the non-executive Director; and Mr. SONG Ruilin, Mr. WANG Jianguo and Mr. WANG Xinhua as the independent non-executive Directors.